Skip to content
value.today

Entact Bio, Inc.

Total raised
$50 M
2 rounds on record
Latest round
$10 M
Jan 2026
First round on record
Jan 2024
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Entact Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$10 MNo. 2$10 to $50 million

Entact Bio, Inc.: Raise no. 2, Jan 2026

Investors in this round

7 investors had bought by the notice of Jun 3, 2026: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Victoria Richon · Executive Officer, Director, Promoter
  • Andrew Sinclair · Director
  • Anna French · Director
  • Owen Smith · Director
  • Pini Orbach · Director
  • Richard Gaster · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Victoria Richon, Chief Executive Officer and Director of the Issuer. Source: SEC Form D, newest notice filed Jun 3, 2026. Read the notice at the SEC.

equitySEC
Jan 2024$40 MNo. 1$10 to $50 million

Entact Bio, Inc.: Raise no. 1, Jan 2024

Investors in this round

7 investors had bought by the notice of May 15, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Victoria Richon · Executive Officer, Director
  • Alon Lazarus · Director
  • Andrew Sinclair · Director
  • Anna French · Director
  • Owen Smith · Director
  • Richard Gaster · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Victoria Richon, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed May 15, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Entact Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

That is all the official record says: Entact Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Entact Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Entact Bio, Inc.
NameRoleNamed in
Victoria RichonExecutive officerJun 2026
Andrew SinclairDirectorJun 2026
Anna FrenchDirectorJun 2026
Owen SmithDirectorJun 2026
Pini OrbachDirectorJun 2026
Richard GasterDirectorJun 2026
Victoria RichonDirectorJun 2026
Alon LazarusDirectorMay 2024
Victoria RichonPromoterJun 2026